226 related articles for article (PubMed ID: 28700899)
21. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
[TBL] [Abstract][Full Text] [Related]
22. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
24. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
[TBL] [Abstract][Full Text] [Related]
25. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
26. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
Jiang W; Lionberger R; Yu LX
Bioanalysis; 2011 Feb; 3(3):333-44. PubMed ID: 21320053
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin.
Hekmatirad S; Moloudizargari M; Moghadamnia AA; Kazemi S; Mohammadnia-Afrouzi M; Baeeri M; Moradkhani F; Asghari MH
Front Immunol; 2021; 12():692654. PubMed ID: 34149737
[TBL] [Abstract][Full Text] [Related]
29. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
[TBL] [Abstract][Full Text] [Related]
30. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446
[TBL] [Abstract][Full Text] [Related]
31. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.
Vail DM; Amantea MA; Colbern GT; Martin FJ; Hilger RA; Working PK
Semin Oncol; 2004 Dec; 31(6 Suppl 13):16-35. PubMed ID: 15717736
[TBL] [Abstract][Full Text] [Related]
32. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
33. Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).
Boers-Sonderen MJ; van Herpen CM; van der Graaf WT; Desar IM; van der Logt MG; de Beer YM; Ottevanger PB; van Erp NP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):457-63. PubMed ID: 24965180
[TBL] [Abstract][Full Text] [Related]
34. The release of Doxorubicin from liposomes monitored by MRI and triggered by a combination of US stimuli led to a complete tumor regression in a breast cancer mouse model.
Rizzitelli S; Giustetto P; Faletto D; Delli Castelli D; Aime S; Terreno E
J Control Release; 2016 May; 230():57-63. PubMed ID: 27049069
[TBL] [Abstract][Full Text] [Related]
35. Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.
Blaha M; Martinkova J; Lanska M; Filip S; Malakova J; Kubecek O; Bezouska J; Spacek J
Atheroscler Suppl; 2017 Nov; 30():286-293. PubMed ID: 29096853
[TBL] [Abstract][Full Text] [Related]
36. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
37. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.
Pramanik D; Campbell NR; Das S; Gupta S; Chenna V; Bisht S; Sysa-Shah P; Bedja D; Karikari C; Steenbergen C; Gabrielson KL; Maitra A; Maitra A
Oncotarget; 2012 Jun; 3(6):640-50. PubMed ID: 22791660
[TBL] [Abstract][Full Text] [Related]
38. Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center.
Khallaf SM; Roshdy J; Ibrahim A
J Egypt Natl Canc Inst; 2020 Apr; 32(1):20. PubMed ID: 32372114
[TBL] [Abstract][Full Text] [Related]
39. [Safety of PLD in the treatment of the patients with recurrent ovarian cancer--clinical experience].
Malkowska-Walczak B; Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2009 Sep; 80(9):682-6. PubMed ID: 19886242
[TBL] [Abstract][Full Text] [Related]
40. Microformulations and Nanoformulations of Doxorubicin for Improvement of Its Therapeutic Efficiency.
Alavi M; Nokhodchi A
Crit Rev Ther Drug Carrier Syst; 2020; 37(6):591-611. PubMed ID: 33426834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
